Clinical Trial Update: Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab in patients with persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer has completed; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-05-12